Artiva Biotherapeutics (ARTV) Jefferies London Healthcare Conference 2024 summary

Platform and differentiation

• Utilizes non-genetically modified NK cells combined with monoclonal antibodies, enabling high scalability, low cost, and consistent product quality.

• Demonstrated efficacy in oncology comparable to engineered off-the-shelf products, with a unique safety profile that decouples efficacy from cytokine release syndrome (CRS).

• NK cell approach allows for outpatient administration, unlike T-cell therapies that often require hospitalization due to CRS risk.

Clinical development and trial updates

• Pivoted focus from oncology to autoimmunity after recognizing challenges in competing with established CAR-T therapies.

• Currently running two trials: a company-sponsored lupus trial and an investigator-initiated basket trial (RA, lupus, pemphigus, vasculitis).

• Initial data from these trials expected in the first half of next year, with a focus on both safety and efficacy.

Efficacy, safety, and biomarker strategy

• Aims to achieve deep, durable B-cell depletion and drug-free remission, with a safety profile suitable for community settings.

• Collecting comprehensive biomarker data, including B-cell depletion and autoantibody reduction, but acknowledges challenges in replicating holistic "reset" seen in pioneering studies.

• Durability and reduction in medication use are key clinical goals, with ongoing evaluation of biomarker significance.